The state of the (sentinel) lymph node and tumour microenvironment in patients with HPV-positive and HPV-negative cancer of the vulva.
Recruiting
- Conditions
- vulva carcinomavulvar cancer10038594
- Registration Number
- NL-OMON44257
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Age >= 18 years at start of the study;
Primary carcinoma of the vulva with an indication for sentinel node procedure or inguinofemoral lymphadenectomy;
Operation at the NKI-AVL or AMC/VUmc;
Signed informed consent.
Exclusion Criteria
Patiënts < 18 years at start of the study;
Patiënts who had previous therapy for macro invasive vulvar cancer (including sentinel node procedure) will not participate in the sentinel node part of the study.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do immune cell infiltration patterns in sentinel lymph nodes differ between HPV-positive and HPV-negative vulvar cancer in NL-OMON44257?
What is the prognostic value of sentinel lymph node status compared to traditional staging in HPV-related vulvar carcinoma (NCT ID: NL-OMON44257)?
Which tumor microenvironment biomarkers predict response to immunotherapy in HPV-positive vs. HPV-negative vulvar cancer (NCT ID: NL-OMON44257)?
What are the adverse event profiles of sentinel lymph node biopsy in patients with vulvar cancer subtypes (NCT ID: NL-OMON44257)?
How do PD-1/PD-L1 inhibitors compare to other targeted therapies for HPV-positive vulvar cancer based on microenvironment studies from NL-OMON44257?